 Allogene Therapeutics NASDAQ: ALLO shares are trading higher Tuesday after Stifel upgraded the stock from Hold to Buy and raised its price target from 33 to 43 per share. Allogene is a U.S.-based clinical-stage immuno-oncology company. 